tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Ricordi C et al. Donor bone marrow cell infusion without recipient cytoablation induces acceptance of rat islet allografts. 1994 Transplant. Proc. pmid:7527967
Kobayashi M et al. Production of monoclonal antibody against recombinant human FKBP-12 and subcellular localization of FKBP-12 in human mononuclear and polymorphonuclear cells. 1993 Transplant. Proc. pmid:7679832
Friob MC et al. A combined HPLC-ELISA evaluation of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721265
Nakajima H and Oka T The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506. 1996 Transplant. Proc. pmid:8623224
Samuel D et al. Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. 1998 Transplant. Proc. pmid:9636563
Goto Y et al. Outcome of tacrolimus-treated renal transplantation from elderly donors. 2000 Transplant. Proc. pmid:11119908
Chang HY et al. Long-term follow-up of arrhythmia characteristics and clinical outcomes in heart transplant patients. 2013 Jan-Feb Transplant. Proc. pmid:23375324
Matevossian E et al. Liver transplantation in the rat: single-center experience with technique, long-term survival, and functional and histologic findings. 2009 Jul-Aug Transplant. Proc. pmid:19715990
Müller H et al. Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile. 2008 Transplant. Proc. pmid:18454992
Mazali FC et al. Posttransplant diabetes mellitus: incidence and risk factors. 2008 Transplant. Proc. pmid:18455010
de la Fuente S et al. Long-term survivors after pediatric liver transplatation are at increased risk for development of cardiovascular disease events: analysis of 30 cases. 2014 Transplant. Proc. pmid:25420837
McKenna BA et al. Tacrolimus (FK 506): a whole blood assay as measured on the Abbott IMx analyzer. 1996 Transplant. Proc. pmid:8623491
Tanida I et al. Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. 1991 Transplant. Proc. pmid:1721297
Stratta RJ et al. FK 506 induction and rescue therapy in pancreas transplant recipients. 1996 Transplant. Proc. pmid:8623492
Ringe B et al. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11120285
O'Neill EA et al. The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. 1991 Transplant. Proc. pmid:1721298
Walker S et al. Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis. 1998 Transplant. Proc. pmid:9636618
Watanabe K et al. Donor bone marrow cell infusion is effective in inducing tolerance in dogs treated with fractionated lymphoid irradiation and FK506. 2000 Transplant. Proc. pmid:11120286
Schulz T et al. Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin. 1998 Transplant. Proc. pmid:9636623
Perrella A et al. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience. 2010 Transplant. Proc. pmid:20534267
Alloway R et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. 2005 Transplant. Proc. pmid:15848559
Chen JS et al. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. 2009 Transplant. Proc. pmid:19545678
Cabello M et al. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. 2010 Transplant. Proc. pmid:20970603
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Imai K et al. Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. 1990 Transplant. Proc. pmid:1697117
Erickson L et al. Gene expression profiling of acute rejection and mixed lymphocyte reaction with tacrolimus immunosuppression. 2002 Transplant. Proc. pmid:12176407
Orita T et al. Effect of FK 506 in combination with prednisolone on the graft-vs-host reaction after small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7518147
Graeb C et al. Cytoimmunologic monitoring of small bowel allograft recipients. 1992 Transplant. Proc. pmid:1376515
Fay JW et al. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. 1995 Transplant. Proc. pmid:7533383
Takai K et al. Immunosuppressive effects of FK 506 on rat lymphoid organs. 1991 Transplant. Proc. pmid:1721329
Mizuta K et al. Increase of bile acid production by tacrolimus in the rat liver. 2003 Transplant. Proc. pmid:12591477
van Hooff JP and Christiaans MH Use of tacrolimus in renal transplantation. 1999 Transplant. Proc. pmid:10616483
Mitsuoka N et al. Cytokinic character of graft infiltrate versus peripheral blood lymphocytes during calcineurin inhibitor-resistant small bowel transplantation in rats. 2003 Transplant. Proc. pmid:12591532
Charco R et al. CD28 regulation in liver transplant recipients treated with two different immunosuppressive regimens. 1999 Transplant. Proc. pmid:10616508
Loucaidou M et al. Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression. 2005 Transplant. Proc. pmid:15919456
Hoshinaga K et al. Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. 2005 Transplant. Proc. pmid:15919457
Ping X et al. Antigen sampling on the Peyer's patches in a murine small bowel transplantation model. 2010 Transplant. Proc. pmid:21094860
Signorell J et al. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. 2010 Transplant. Proc. pmid:21094874
Scantlebury VP et al. Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. 1995 Transplant. Proc. pmid:7533436
Hanafusa T et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. 1995 Transplant. Proc. pmid:7533440
Shapiro R et al. FK 506 in clinical kidney transplantation. 1991 Transplant. Proc. pmid:1721361
Todo S et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. 1991 Transplant. Proc. pmid:1703340
Pascual J et al. Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney transplantation: results of a European trial with 3-year follow up. 2003 Transplant. Proc. pmid:12962764
Lyne JC et al. Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up. 1997 Feb-Mar Transplant. Proc. pmid:9123015
Sugitani A et al. Intestinal neurons in acute and chronic rejection after small bowel transplantation in dogs. 1996 Transplant. Proc. pmid:8907941
Charpentier B A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients. 2002 Transplant. Proc. pmid:12176511
Borda B et al. Functional and histopathologic changes in renal transplant patients with new-onset diabetes and dyslipidemia. 2011 Transplant. Proc. pmid:21620104
Krzyżowska K et al. No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients. Transplant. Proc. pmid:30056895
Zmonarski S et al. Expression of PBMC TLR4 in Renal Graft Recipients Who Experienced Delayed Graft Function Reflects Dynamic Balance Between Blood and Tissue Compartments and Helps Select a Problematic Patient. Transplant. Proc. pmid:30056893
Kim K et al. Everolimus-Induced Systemic Serositis After Simultaneous Liver and Kidney Transplantation: A Case Report. Transplant. Proc. pmid:28104132
Weir M Impact of immunosuppressive regimes on posttransplant diabetes mellitus. 2001 Transplant. Proc. pmid:11498201
Kaibori M et al. Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes. 1999 Feb-Mar Transplant. Proc. pmid:10083347
Terakura M et al. Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083380
Yokota K et al. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. 1989 Transplant. Proc. pmid:2468209
Carroll PB et al. Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. 1991 Transplant. Proc. pmid:1721394
Inagaki K et al. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. 1989 Transplant. Proc. pmid:2468210
Scantlebury V et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. 1991 Transplant. Proc. pmid:1721395
Lee S et al. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. 2010 Transplant. Proc. pmid:20430174
Kim JM et al. Preemptive therapy in adult liver transplant recipients in CMV-endemic area. 2010 Transplant. Proc. pmid:20430182
el-Ghoroury M et al. Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123461
Ali IH et al. Incidence and risk factors for post-renal transplant diabetes mellitus. 2011 Transplant. Proc. pmid:21440763
Hariharan S et al. Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123462
Koefoed-Nielsen PB and Jørgensen KA Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. 2002 Transplant. Proc. pmid:12176559
McGrath JS and Shehata M Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. 2001 Transplant. Proc. pmid:11377500
Mueller AR et al. Long-term follow-up in hepatitis C patients with respect to immunosuppression. 1996 Transplant. Proc. pmid:8962255
Baid S et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. 2002 Transplant. Proc. pmid:12176569
Kelly JS and Sharkey J Immunosuppressants-ligands as neuroprotectants. 2001 Transplant. Proc. pmid:11377506
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Akioka K et al. Diabetes in renal transplant recipients treated with tacrolimus. 2002 Transplant. Proc. pmid:12176570
Abouljoud M et al. Conversion to neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. 2001 Feb-Mar Transplant. Proc. pmid:11267175
Murase N et al. Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721424
Takeda M et al. Pretreatment with splenectomy and FK506 in xeno-lung transplantation. 1996 Transplant. Proc. pmid:8658728
Tanaka H et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. 1987 Transplant. Proc. pmid:2445067
Berweck S et al. Clinical use of the euglycemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9723345
Neff GW et al. Ten years of sirolimus therapy in orthotopic liver transplant recipients. 2003 Transplant. Proc. pmid:12742498
Petz W et al. Experience with the use of basiliximab in liver transplantation--use in pediatric and adult recipients in combination with cyclosporine or tacrolimus. 2002 Transplant. Proc. pmid:12176648
Jain A et al. Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. 2002 Transplant. Proc. pmid:12176649
Heffron TG et al. Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients. 2001 Feb-Mar Transplant. Proc. pmid:11267368
Yoshimura R et al. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7524223
Groetzner J et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? 2001 Feb-Mar Transplant. Proc. pmid:11267373
Kupferman JC et al. Activation of the renal renin-angiotensin system by cyclosporine A and FK 506 in the rat. 1994 Transplant. Proc. pmid:7524224
van den Berg AP et al. Recurrent HCV infection reduces the requirement for tacrolimus after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267375
Liversidge J et al. FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. 1991 Transplant. Proc. pmid:1721455
Bárcena R et al. Immunosuppression in liver transplantation: a European survey. 1999 Transplant. Proc. pmid:10500654
Pretagostini R et al. Delayed Introduction of Everolimus in De Novo Renal Transplanted Patients: A Single-Center Experience. 2016 Transplant. Proc. pmid:27109947
Mochizuki M et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. 1991 Transplant. Proc. pmid:1721456
Chávez R et al. Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. 1999 Transplant. Proc. pmid:10500655
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201
Ginevri F et al. Expression of collagen by renal fibroblasts treated with FK 506 in vitro. 1998 Transplant. Proc. pmid:9636387
Dall'Agnol DJ et al. Effects of immunosuppressive drugs on gastrointestinal transit of rats: effects of tacrolimus, cyclosporine, and prednisone. Transplant. Proc. pmid:25131057
Iwata H et al. Prolongation of xenograft survival by combining donor-specific intravenous presensitization with FK 506. 2002 Transplant. Proc. pmid:12431592
Rong G et al. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. 2010 Transplant. Proc. pmid:21094796
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
van Hooff JP et al. Preservation of renal function and cardiovascular risk factors. 2006 Transplant. Proc. pmid:16979974
Guleria S et al. Tacrolimus (Pan Graf) as de novo therapy in renal transplant recipients in India. 2006 Transplant. Proc. pmid:16979989
Katayama Y et al. Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. 1991 Transplant. Proc. pmid:1703690
Takaya S et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. 1991 Transplant. Proc. pmid:1703691
Carl S et al. Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept. 1998 Transplant. Proc. pmid:9636502
Budde K et al. Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 months. 1998 Transplant. Proc. pmid:9636503